ImaginAb

ImaginAb, Inc. operates as a clinical-stage biotechnology firm focused on advancing immuno-oncology through the development of imaging agents and radiopharmaceutical therapies. Founded in 2007 by Robert Reiter, Anna Wu, and Christian P. Behrenbruch, the company emerged from research conducted at the University of California, Los Angeles (UCLA), with the goal of creating more precise, non-invasive methods for visualizing the immune system's response to cancer. The founders' collective expertise laid the groundwork for the company's technological platform; Anna Wu is a distinguished figure in molecular immunology and antibody engineering, while Robert Reiter is a renowned surgeon and scientist in prostate cancer research. Christian P. Behrenbruch brought commercialization and venture capital experience to the founding team.

The company's core technology revolves around its proprietary 'minibody' and 'cys-diabody' platforms, which are engineered antibody fragments designed for rapid targeting and clearance within the body. This enables quicker and clearer in-vivo imaging compared to full-sized monoclonal antibodies. Its lead product, 89Zr crefmirlimab berdoxam, also known as CD8 ImmunoPET™, is an imaging agent that targets the CD8 biomarker on T-cells. This allows physicians to visualize the concentration and location of a patient's CD8+ T-cells, which are crucial for fighting tumors, thereby providing a whole-body view of the immune response to cancer therapies. The agent is currently in Phase II clinical trials.

ImaginAb's business model is multifaceted, generating revenue primarily through strategic licensing and collaboration agreements. The company partners with numerous pharmaceutical and biotechnology companies, licensing its CD8 ImmunoPET™ agent for use in their respective immunotherapy clinical trials. These collaborations enable partner firms to better select patients, monitor treatment responses, and assess the efficacy of their novel cancer drugs, creating a significant value proposition within the drug development market. By providing a tool that can potentially de-risk and accelerate clinical trials for immuno-oncology treatments, ImaginAb has positioned itself as a key enabler in the oncology space. The company's headquarters are located in Inglewood, California.

Keywords: immuno-oncology, PET imaging, radiopharmaceutical therapy, CD8 T-cells, minibody platform, clinical trials, cancer diagnostics, antibody engineering, molecular imaging, oncology drug development